Phaseline

Targets › LDLR

LDLR (Low-density lipoprotein receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Sep 2027.

Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. (UniProt, P01130)

Open in Phaseline: the race on LDLR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EMSBERLIM 25/20 ASSOCIATION
SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta
SGLT2, LDLRPhase 3Dyslipidemia Associated With Type II Diabetes MellitusSep 2027
Cedars-Sinai Medical CenterVytorin
Cholesterol absorption inhibitor (ezetimibe) and HMG-CoA reductase inhibitor (simvastatin)
LDLRPhase 2Prostate CancerFeb 2028

Conditions

Prostate Cancer (1) Dyslipidemia Associated With Type II Diabetes Mellitus (1)

Modalities

small molecule (2)

Companies

Cedars-Sinai Medical Center (1) EMS (1)

Related targets

SGLT2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.